Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia

Next Previous
Trial Profile

Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dipeptidyl peptidase 4 inhibitors (Primary) ; Empagliflozin (Primary) ; Sodium-glucose transporter 2 inhibitors (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms EMPRISE; EMPRISE EU-Asia
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 26 Jun 2023 Final year results (n=21860) presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 26 Dec 2022 Results assessing effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in Swedish clinical practice, published in the Diabetes, Obesity and Metabolism.
  • 09 Nov 2022 Results assessing the annual costs savings arising from the reduction in the rates of healthcare resource utilization arising from the use of empagliflozin over dipeptidyl peptidase-4 inhibitors in select Asia-Pacific countries (Australia, Indonesia, Malaysia, Philippines, Thailand and Vietnam), presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top